Beta Bionics Announces Board Appointment of Gerard Michel
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of...
Clinical Trial
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press...
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent...
Tempest Reports Year End 2024 Financial Results and Provides Business Update
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma...
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune...
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four...
Alzheimer’s Early Detection Tests Using Video Games Could Be As Effective as Blood Tests and Boost Clinical Trials
Tests Were Created by Rutgers-Newark Researchers NEWARK, N.J., March 27, 2025 /PRNewswire/ -- Alzheimer's early detection tests using video games developed...
WCG ClinSphere™ Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection
CARY, N.C., March 27, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical...
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in...
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for...
Alzheimer’s Data Challenge Names Winners for Innovative Biomarker Research Competition
Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data CompetitionWASHINGTON, March 27, 2025 (GLOBE NEWSWIRE) -- International non-profit organization The...
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE)...
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has...
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-...
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel,...
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives...
Organovo Provides Business Update
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology...
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer...
SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer
Chetan Pujara, Ph.D Chief Research & Development Officer, SpyGlass Pharma Dr. Pujara brings extensive industry experience to guide late-stage development...
Evaxion to announce business update and full year 2024 financial results on April 1, 2025
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™...